Black Patients With Prostate Cancer Treated With Surgery More Likely to Experience Adverse Events

Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events.
Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events.

Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events and incur higher costs than non-Hispanic white patients, a new study published online ahead of print in JAMA Oncology has shown. Fortunately, these negative effects do not translate to a disparity in cancer-specific or all-cause mortality.

Because there has been much data suggesting that black men with localized prostate cancer have a higher rate of cancer-specific mortality compared with white patients, researchers sought to assess racial disparities in the use, quality of care, and outcomes of radical prostatectomy in elderly men with localized prostate cancer.

For the retrospective analysis, researchers analyzed data from 2,020 black patients and 24,462 white patients age 65 years or older with localized prostate cancer who underwent radical prostatectomy within the first year of diagnosis between 1992 and 2009 from the SEER-Medicare database.

Results showed that black patients experienced a 7-day treatment delay compared with non-Hispanic white patients, had a higher risk of postoperative emergency department visits and readmissions both within 30 days of surgery and after 30 days or more, and incurred higher incremental annual costs.

However, there was no difference in prostate cancer-specific mortality or all-cause mortality between the 2 patient populations.

“Because the unfavorable quality of care did not translate into worse overall and cancer-specific survival in our sample, the commonly perceived detrimental survival in black patients with PCa may be the sequelae of barriers and selection bias in definitive treatment,” the authors conclude. “Public and professional awareness needs to be raised to address these concerning issues and identify their underlying causes.”

Reference

  1. Schmid M, Meyer CP, Reznor G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer [published online ahead of print October 22, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.3384.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs